KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShort-Term Debt repayments
Ratios

Pfizer (PFE) Accumulated Depreciation & Amortization (2016 - 2025)

Pfizer (PFE) has disclosed Accumulated Depreciation & Amortization for 17 consecutive years, with $6.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 6.0% to $6.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $6.6 billion, a 6.0% decrease, with the full-year FY2025 number at $6.6 billion, down 6.0% from a year prior.
  • Accumulated Depreciation & Amortization was $6.6 billion for Q4 2025 at Pfizer, up from $4.9 billion in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $7.0 billion in Q4 2024 to a low of $1.5 billion in Q2 2023.
  • A 5-year average of $4.0 billion and a median of $4.1 billion in 2022 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: crashed 43.46% in 2024, then soared 87.46% in 2025.
  • Pfizer's Accumulated Depreciation & Amortization stood at $5.2 billion in 2021, then decreased by 2.45% to $5.1 billion in 2022, then rose by 24.21% to $6.3 billion in 2023, then grew by 11.49% to $7.0 billion in 2024, then fell by 6.0% to $6.6 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Accumulated Depreciation & Amortization are $6.6 billion (Q4 2025), $4.9 billion (Q3 2025), and $3.2 billion (Q2 2025).